Truist Maintains Buy Rating on Exponent (EXPO) While Cutting Price Target to $90

Core Insights - Exponent, Inc. (NASDAQ:EXPO) is recognized as one of the 15 overlooked dividend stocks to consider for investment [1] - Truist has maintained a Buy rating on Exponent while reducing its price target from $100 to $90, citing potential opportunities in artificial intelligence and risks from automation [2] - The company reported strong third-quarter performance with double-digit net revenue growth, particularly in dispute-related work across various sectors [3][4] Financial Performance - For Q3 2025, Exponent's total revenue increased by 8% to $147.1 million, while revenue before reimbursements rose by 10% to $137.1 million, compared to $136.3 million and $125.1 million in the same period last year [4] - The growth was driven by a diversified portfolio, with notable strength in sectors such as energy, transportation, life sciences, and construction [3][4] Industry Context - The integration of artificial intelligence into safety-critical systems presents new opportunities for Exponent as clients seek expertise in managing risks [3] - However, the consulting sector may face challenges from increased efficiencies due to automation, potentially impacting billable hours [2]